Brought to you by 
Novartis uses ImmunoGen's TAP to create cancer compounds
13 May 2016
Executive Summary
Novartis AG licensed exclusive rights to use ImmunoGen Inc.'s (cancer therapeutics) Targeted Antibody Payload (TAP) technology to develop antibodies against a predetermined number of oncology targets chosen by the Big Pharma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis uses ImmunoGen's TAP to create cancer compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice